Results of Operations and Financial Condition. On July 29, 2026, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the second fiscal quarter ended June 30, 2026. A copy of the Company’s press release dated July 29, 2026, titled “Pulmonx Reports Second Quarter 2026 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished under “

Results of Operations and Financial Condition. On April 29, 2026, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the first fiscal quarter ended March 31, 2026. A copy of the Company’s press release dated April 29, 2026, titled “Pulmonx Reports First Quarter 2026 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished under “

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Entry into a Material Definitive Agreement. Perceptive Credit Facility On March 2, 2026 (the “Closing Date”), Pulmonx Corporation (the “Company”) entered into a Credit Agreement and Guaranty (the “Credit Agreement”) and a Security Agreement (the “Security Agreement”), with Perceptive Credit Holdings V, LP (“Perceptive”), as the initial lender, administrative agent and collateral agent. The Perceptive Credit Agreement provides for a senior secured term loan facility in an aggregate principal a…

Termination of a Material Definitive Agreement. CIBC Credit Agreement In connection with the Company’s entry into the Loan Facility, on March 2, 2026, the Company repaid all outstanding indebtedness under the Amended and Restated Loan and Security Agreement, dated March 29, 2021, as amended, among the Company and the Canadian Imperial Bank of Commerce, as lender, and terminated all its obligations and commitments thereunder. No early termination fees or penalties were incurred by the Company…

Unregistered Sales of Equity Securities. The information set forth in

Results of Operations and Financial Condition. On March 4, 2026, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the fourth fiscal quarter and year ended December 31, 2025. A copy of the Company’s press release dated March 4, 2026, titled “Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is bein…

Results of Operations and Financial Condition. On November 12, 2025, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the third fiscal quarter ended September 30, 2025. A copy of the Company’s press release dated November 12, 2025, titled “Pulmonx Reports Third Quarter 2025 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished under “

Results of Operations and Financial Condition. On October 27, 2025, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the third fiscal quarter ended September 30, 2025. A copy of the Company’s press release dated October 27, 2025, titled “Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit her…

President and Chief Executive Officer — Steven S. Williamson: Steven S. Williamson resigned as President and CEO, with Glendon E. French appointed to succeed him.

Results of Operations and Financial Condition. On July 30, 2025, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the second fiscal quarter ended June 30, 2025. A copy of the Company’s press release dated July 30, 2025, titled “Pulmonx Reports Second Quarter 2025 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished under “

Results of Operations and Financial Condition. On April 30, 2025, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the first fiscal quarter ended March 31, 2025. A copy of the Company’s press release dated April 30, 2025, titled “Pulmonx Reports First Quarter 2025 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished under “

Results of Operations and Financial Condition. On February 19, 2025, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the fourth fiscal quarter and year ended December 31, 2024. A copy of the Company’s press release dated February 19, 2025, titled “Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit…

Results of Operations and Financial Condition. On October 30, 2024, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the third fiscal quarter ended September 30, 2024. A copy of the Company’s press release dated October 30, 2024, titled “Pulmonx Reports Third Quarter 2024 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished under “

Results of Operations and Financial Condition. On July 31, 2024, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the second fiscal quarter ended June 30, 2024. A copy of the Company’s press release dated July 31, 2024, titled “Pulmonx Reports Second Quarter 2024 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished under “

Entry into a Material Definitive Agreement. On May 17, 2024, Pulmonx Corporation (the “Company”) entered into that certain Third Amendment to Office Lease (the “Third Amendment to Office Lease”) to its existing lease agreement (the “Original Lease” and, as amended by the Third Amendment to Office Lease, the “Lease”) with HCP LS Redwood City, LLC (the “Landlord”), whereby the Landlord leases to the Company 24,591 rentable square feet of space (the “Existing Premises”) consisting of all of the…

Results of Operations and Financial Condition. On May 1, 2024, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the first fiscal quarter ended March 31, 2024. A copy of the Company’s press release dated May 1, 2024, titled “Pulmonx Reports First Quarter 2024 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished under “

Chief Financial Officer and Principal Financial and Accounting Officer — Mehul Joshi: The company appointed a new Chief Financial Officer and Principal Financial and Accounting Officer.

President and Chief Executive Officer — Glendon E. French: Mr. French resigned as CEO but will continue in a reduced role and on the board.

Results of Operations and Financial Condition. On February 21, 2024, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the fourth fiscal quarter and year ended December 31, 2023. A copy of the Company’s press release dated February 21, 2024, titled “Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto)…

Results of Operations and Financial Condition. On October 30, 2023, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the third fiscal quarter ended September 30, 2023. A copy of the Company’s press release dated October 30, 2023, titled “Pulmonx Reports Record Third Quarter 2023 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished…

Results of Operations and Financial Condition. On October 10, 2023, Pulmonx Corporation (the “ Company ”) issued a press release announcing its preliminary unaudited revenue results for the third fiscal quarter ended September 30, 2023. A copy of the Company’s press release dated October 10, 2023 titled “Pulmonx Announces CFO Transition and Record Preliminary Third Quarter 2023 Revenue” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (incl…

Chief Financial Officer — Derrick Sung, Ph.D.: Dr. Sung stepped down to pursue a new business opportunity.

Results of Operations and Financial Condition. On August 2, 2023, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the second fiscal quarter ended June 30, 2023. A copy of the Company’s press release dated August 2, 2023, titled “Pulmonx Reports Second Quarter 2023 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished under “

Results of Operations and Financial Condition. On May 2, 2023, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the first fiscal quarter ended March 31, 2023. A copy of the Company’s press release dated May 2, 2023, titled “Pulmonx Reports First Quarter 2023 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished under “